Gordon MacLeod - Ryman Healthcare CFO, Deputy Chief Executive and Company Secretary
| RYHTY Stock | USD 13.05 0.20 1.51% |
CFO
Mr. Gordon MacLeod is Chief Executive Officer of the Company. He had previously been a corporate fi nance partner with PwC and fi nance director of a London listed hitech engineering company. Gordy has a Bachelor of Commerce degree and is a chartered accountant. He is a board member of the New Zealand Aged Care Association and the Retirement Villages Association. since 2017.
| Tenure | 7 years |
| Phone | 64 3 366 4069 |
| Web | https://www.rymanhealthcare.co.nz |
Ryman Healthcare Management Efficiency
Ryman Healthcare's management efficiency ratios could be used to measure how well Ryman Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | CFO Age | ||
| David Duckworth | Acadia Healthcare | 44 | |
| Yaw Yap | Concord Medical Services | 56 | |
| Suzanne Snapper | The Ensign Group | 50 | |
| Michael Malatesta | Select Medical Holdings | 54 | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | -7.0E-4 |
Ryman Healthcare Leadership Team
Elected by the shareholders, the Ryman Healthcare's board of directors comprises two types of representatives: Ryman Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ryman. The board's role is to monitor Ryman Healthcare's management team and ensure that shareholders' interests are well served. Ryman Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ryman Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Claire Higgins, Non-Executive Independent Director | ||
| Anthony Leighs, Independent Director | ||
| Cameron Holland, Chief Australia | ||
| Richard Umbers, Group Exec | ||
| Gordon MacLeod, CFO, Deputy Chief Executive and Company Secretary | ||
| Kevin Hickman, Co-Founder, Director and Member of Remuneration and Nominations Committee | ||
| Taylor Allison, Design Manager | ||
| Michelle Perkins, IR Contact Officer | ||
| Simon Challies, CEO, Managing Director, Executive Director | ||
| Tom Brownrigg, Construction Manager | ||
| Jo Appleyard, Independent Non-Executive Director | ||
| Jenn Poskitt, Marketing Manager | ||
| Philip Mealings, Property and Purchasing Manager | ||
| George Savvides, Independent Director | ||
| Douglas McKay, Independent Director | ||
| Cheyne Chalmers, Chief Zealand | ||
| Debbie McClure, Group Sales Manager | ||
| Warren Bell, Independent Non-Executive Director | ||
| David Bennett, Group Officer | ||
| Deborah Marris, G Sec | ||
| Marsha Cadman, Chief Officer | ||
| Rick Davies, Chief Officer | ||
| Andrew Mitchell, Development Manager | ||
| David Kerr, Independent Non-Executive Chairman of the Board | ||
| Geoffrey Cumming, Director | ||
| MaryAnne Stone, Chief Officer | ||
| David King, Corporate Affairs Manager | ||
| Chris BE, Chief Officer | ||
| Barbara ReynenRose, Operations & Clinical Services Manager | ||
| Nicole Forster, Group Shared Services Manager |
Ryman Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ryman Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | -7.0E-4 | |||
| Profit Margin | 1.13 % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 3.91 B | |||
| Shares Outstanding | 100 M | |||
| Price To Earning | 10.13 X | |||
| Price To Book | 0.85 X | |||
| Price To Sales | 3.74 X | |||
| Revenue | 503.76 M |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ryman Healthcare Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Ryman Pink Sheet analysis
When running Ryman Healthcare's price analysis, check to measure Ryman Healthcare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ryman Healthcare is operating at the current time. Most of Ryman Healthcare's value examination focuses on studying past and present price action to predict the probability of Ryman Healthcare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ryman Healthcare's price. Additionally, you may evaluate how the addition of Ryman Healthcare to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |